Drug Discovery Outsourcing Market

Drug Discovery Outsourcing Market Size and Share Forecast Outlook (2023 to 2033)

The drug discovery outsourcing market is expected to expand its roots at a steady CAGR of 7.2% during the forecast period. The market is likely to hold a revenue of USD 3.75 billion in 2023, while it is anticipated to cross a value of USD 7.52 billion by 2033.

The research report on the drug discovery outsourcing market states that the pharmaceutical industry is expanding thoroughly with new extensions and high-end research programs. The higher penetration of smart technology in the drug discovery and development process is likely to transform the market condition. Furthermore, AI drug discovery outsourcing is much cheaper, easy, and integrated. Thus, pharmaceutical brands adopt these newly designed methods to increase reliability and promote cruelty-free discovery. Alongside this, the growing outsourcing trend in Asian economies like India and China is likely to strengthen the pharmaceutical ties between the West and East. The wave of novel drug discovery in India, with brands building their projects around the Indian drug discovery outsourcing space, is anticipated to flourish the market growth. Moreover, the government projects and the bilateral relationship are also anticipated to increase drug production. This pushes pharma companies to look for biomedical advancements.

The market dynamics have been affected by the pandemic, the geriatric population, and new diseases spreading out of nations. Thus, the consumption of advanced drugs, drug mixtures (synergistic drugs), and other anti-infection drugs are likely to put pressure on the brands. This leads pharmaceutical companies to reach out to distant markets to reduce the cost of production and research of drug discovery and development.

The use of stimulating organs coupled with organs-on-chips for disease modeling and drug development is likely to change the market dynamic. From hit confirmation to lead optimization and high-speed screening services, the smart tech has reformed each component of the drug discovery systems. An estimate states that 80% of the research for different pharmaceutical elements can be outsourced. Thus, the drug discovery outsourcing market is likely to garner during the forecast period.

Attributes	Details
Drug Discovery Outsourcing Market CAGR (2023 to 2033)	7.2%
Drug Discovery Outsourcing Market Size (2023)	USD 3.75 billion
Drug Discovery Outsourcing Market Size (2033)	USD 7.52 billion

Comparison of Historical vs Future Outlook on Drug Discovery Outsourcing Market (2018 to 2022 vs. 2023 to 2033)

According to FMI analysis, the drug discovery outsourcing market was valued at USD 3.50 billion in 2022 and is likely to be worth USD 7.52 billion by 2033.

• Short-term Growth (2023 to 2026): This period is expected to be game-changing for the outsourcing market. It is due to the technology and healthcare outsourcing business expansion in Asian economies along with some African states. Furthermore, the government projects under bilateral ties to tackle future healthcare calamities also add value to the market growth. Hence, the market is expected to hold USD 3.75 billion in 2023, while it is likely to reach USD 4.62 billion by 2026.
• Mid-term Growth (2026 to 2029): During the projected period, a primary factor that drives the demand for drug discovery outsourcing services is the surge in new diseases. The new technology is integrated into the expanding smart technologies such as artificial intelligence and advanced healthcare communication. This takes a market value from USD 4.62 billion in 2026 to USD 5.69 billion in 2029.
• Long-term Growth (2029 to 2033): The cheaper research outsourcing and higher demand for new drugs for specific diseases. Pharmaceutical companies collaborate with production factories in emerging economies with high populations and cheap workforces. This period is anticipated to witness steady growth. Thus, the drug discovery outsourcing market is anticipated to thrive at a steady CAGR of 7.2% between 2023 and 2033.

Key Growth Drivers Fueling the Drug Discovery Outsourcing Market

AI-enabled drug discovery methods, along with the expanding research and development programs, are garnering market growth. The increased penetration of innovation, reduced costs, and pharmaceutical companies collaborating for the research part fuel the market growth.

The application of AI in protein modeling, digital organ simulation, and organ-on-a-chip is also easing the drug discovery process. Developing nations like India and China are becoming the center stage for the pharmaceutical revolution with mass drug production and extended research and development programs. The AI-driven drug discovery is anticipated to increase the capital investment in distant lands to expand their production and research workforce. Alongside this, the new AI drug discovery outsourcing services are likely to enhance target identification, patient stratification, and biomarker development.

As COVID-19 pandemic garnered the pharmaceutical industry, new viruses and their penetration in developed nations are also increasing drug consumption. Even developing nations enhancing public health conditions are adopting advanced drug discovery measures. Similarly, they are indulged in collaborating with cheaper third-party research and development vendors.

Key Restraints in the Drug Discovery Outsourcing Market

Key restraints for the drug discovery outsourcing market are governmental restrictions, higher outsourcing costs, and tariffs restraining market growth. The rapidly expanding space for alternative medicine and limited medical budgets are limiting the growth of the market.

Analysis of Top Countries, Producing, Formulating, Packaging, Distributing, and Consuming Drug Discovery Outsourcing Services

Why is the United States Considered a Lucrative Market for Drug Discovery Outsourcing?

Increased Demand for Research and Development along with Expanding Bilateral Ties are making North America the Top Growing Region

North America region leads in terms of the market share in the drug discovery outsourcing market with a market share CAGR of 35.5%. The growth is attributed to lower research costs, higher innovative experiments, and increasing demand for generic and disease-specific drugs. Furthermore, companies collaborating with third-party drug discovery service vendors are likely to impact the market positively. The rising competition is fueled by factors such as higher efficiency, quality, and innovation is garnering regional growth.

How does Japan perform in Drug Discovery Outsourcing Market?

Integration of Smart Technologies coupled with Heavy Demand for Generic Medicine is Fuelling the Demand for Drug Discovery Outsourcing

Asia Pacific region leads the market in terms of CAGR between 2023 and 2033. Japan drug discovery outsourcing markets in the Asia Pacific region. Apart from the higher population and higher investment, the Japanese market comes in the pharmaceutical market due to smart technology integration. The AI-enabled drug discovery method is transforming the industry with fast, reliable, inexpensive, and cruelty-free drug discovery.

What makes the United Kingdom another significant market for Drug Discovery Outsourcing Market?

Concepts like Digital Organ Simulation and Organ-on-a-chip are collectively flourishing the Regional Growth

The United Kingdom is another significant market for drug discovery outsourcing systems. The increase in virus mutations and deadly chronic diseases is pushing the demand for drug discovery outsourcing. Better prediction in human drug discovery also impacts the various treatment garnering market growth.

Drug Discovery Outsourcing Industry Analysis by Category

Category	By Workflow
Leading Segment	Lead Identification & Candidate Optimization
Market Share % (2022)	32.3%

Category	By Therapeutic Area
Leading Segment	Respiratory Systems
Market Share % (2022)	14%

Higher Activity, Increase Selectivity, and Reduced Side Effects are Garnering the Segmental Growth

Based on the workflow, lead identification & candidate optimization held the leading share of 32.3% in 2022. The growth is attributed to better workflow management. Also, increased activity around the non-bonded interaction and reduced side effects are making this segment more popular in the category. It is expected to improve potency and dynamics as well.

Increased Respiratory Diseases post Pandemic along with the Therapeutic Effects are Propelling the Segment’s Growth

Based on the therapeutic area, the respiratory systems segment held a share of 14.0% in 2022. The higher amount of chronic diseases impacting the respiratory organs and developing various chronic and non-chronic diseases are thriving segmental growth. The therapeutic areas involve oncology, ophthalmology, hematology, cardiovascular, endocrine, and others. The diseases like bronchitis, tuberculosis, COPD, and asthma fuel the segment growth.

Competitive Intelligence: Strategic Undertakings Adopted by Market Players

The key players focus on adopting advanced AI-enabled drug discovery outsourcing services. The end users choose the vendors that not only provide better pricing but also efficient quality and timing. Companies also merge, collaborate, and acquire in order to expand their sales and distributional channels.

Market Developments

• EVOTEC has introduced different discovery options for antibody discovery such as integrated drug discovery, integrated CMC, integrated pre-clinical, target ID, and validation services.
• The Genscript has launched small-molecule drugs and large-molecule drug discovery programs that use organic or metallic compounds.

Leading Suppliers in the Drug Discovery Outsourcing Market

• Albany Molecular Research Inc.
• EVOTEC
• Laboratory Corporation of America Holdings
• GenScript
• Pharmaceutical Product Development, LLC
• Charles River
• WuXi AppTec
• Merck & Co., Inc.
• Thermo Fisher Scientific Inc.
• Dalton Pharma Services
• Oncodesign
• Jubilant Biosys
• DiscoverX Corp.
• QIAGEN
• Eurofins SE
• Syngene International Limited
• Dr. Reddy Laboratories Ltd.
• Pharmaron Beijing Co., Ltd.
• TCG Lifesciences Pvt Ltd.
• Domainex Ltd.

Table of Content

• 1. Executive Summary 
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
• 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Workflow
  • 5.1. Target Identification & Screening
  • 5.2. Target Validation & Functional Informatics
  • 5.3. Lead Identification & Candidate Optimization
  • 5.4. Preclinical Development
  • 5.5. Other Associated Workflow
• 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutics Area
  • 6.1. Respiratory system
  • 6.2. Pain and Anaesthesia
  • 6.3. Oncology
  • 6.4. Ophthalmology
  • 6.5. Haematology
  • 6.6. Cardiovascular
  • 6.7. Endocrine
  • 6.8. Gastrointestinal
  • 6.9. Immunomodulation
  • 6.10. Dermatology
  • 6.11. Central Nervous System
  • 6.12. Genitourinary System
• 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
  • 7.1. Small Molecules
  • 7.2. Large Molecules
• 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
  • 8.1. Pharmaceutical and Biotechnology companies
  • 8.2. Academic Institutes
• 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
  • 9.1. North America
  • 9.2. Latin America
  • 9.3. Europe
  • 9.4. South Asia
  • 9.5. East Asia
  • 9.6. Oceania
  • 9.7. MEA
• 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 17. Key Countries Market Analysis
• 18. Market Structure Analysis
• 19. Competition Analysis
  • 19.1. Albany Molecular Research Inc.
  • 19.2. EVOTEC
  • 19.3. Laboratory Corporation of America Holdings
  • 19.4. GenScript
  • 19.5. Pharmaceutical Product Development, LLC
  • 19.6. Merck & Co., Inc.
  • 19.7. Thermo Fisher Scientific Inc.
  • 19.8. Dalton Pharma Services
  • 19.9. Dr. Reddy Laboratories Ltd.
  • 19.10. Pharmaron Beijing Co., Ltd.
  • 19.11. TCG Lifesciences Pvt Ltd.
  • 19.12. Domainex Ltd.
  • 19.13. Eurofins SE
  • 19.14. Syngene International Limited
• 20. Assumptions & Acronyms Used
• 21. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Workflow, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 5: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Workflow, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033

Table 9: North America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 10: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Workflow, 2018 to 2033

Table 13: Latin America Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033

Table 14: Latin America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 15: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: Europe Market Value (US$ Million) Forecast by Workflow, 2018 to 2033

Table 18: Europe Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033

Table 19: Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 20: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: South Asia Market Value (US$ Million) Forecast by Workflow, 2018 to 2033

Table 23: South Asia Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033

Table 24: South Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 25: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 26: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 27: East Asia Market Value (US$ Million) Forecast by Workflow, 2018 to 2033

Table 28: East Asia Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033

Table 29: East Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 30: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 31: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 32: Oceania Market Value (US$ Million) Forecast by Workflow, 2018 to 2033

Table 33: Oceania Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033

Table 34: Oceania Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 35: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 36: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 37: MEA Market Value (US$ Million) Forecast by Workflow, 2018 to 2033

Table 38: MEA Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033

Table 39: MEA Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 40: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033

List of Figures

Figure 1: Global Market Value (US$ Million) by Workflow, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Therapeutics Area, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 9: Global Market Value (US$ Million) Analysis by Workflow, 2018 to 2033

Figure 10: Global Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033

Figure 11: Global Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033

Figure 12: Global Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033

Figure 13: Global Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033

Figure 14: Global Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033

Figure 15: Global Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 16: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 17: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 18: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 19: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 20: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 21: Global Market Attractiveness by Workflow, 2023 to 2033

Figure 22: Global Market Attractiveness by Therapeutics Area, 2023 to 2033

Figure 23: Global Market Attractiveness by Drug Type, 2023 to 2033

Figure 24: Global Market Attractiveness by End User, 2023 to 2033

Figure 25: Global Market Attractiveness by Region, 2023 to 2033

Figure 26: North America Market Value (US$ Million) by Workflow, 2023 to 2033

Figure 27: North America Market Value (US$ Million) by Therapeutics Area, 2023 to 2033

Figure 28: North America Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 29: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Workflow, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033

Figure 37: North America Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033

Figure 38: North America Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033

Figure 39: North America Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033

Figure 40: North America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 41: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 42: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 43: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 44: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 45: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 46: North America Market Attractiveness by Workflow, 2023 to 2033

Figure 47: North America Market Attractiveness by Therapeutics Area, 2023 to 2033

Figure 48: North America Market Attractiveness by Drug Type, 2023 to 2033

Figure 49: North America Market Attractiveness by End User, 2023 to 2033

Figure 50: North America Market Attractiveness by Country, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) by Workflow, 2023 to 2033

Figure 52: Latin America Market Value (US$ Million) by Therapeutics Area, 2023 to 2033

Figure 53: Latin America Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 59: Latin America Market Value (US$ Million) Analysis by Workflow, 2018 to 2033

Figure 60: Latin America Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033

Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033

Figure 62: Latin America Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033

Figure 63: Latin America Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033

Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033

Figure 65: Latin America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 66: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 68: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 69: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 70: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 71: Latin America Market Attractiveness by Workflow, 2023 to 2033

Figure 72: Latin America Market Attractiveness by Therapeutics Area, 2023 to 2033

Figure 73: Latin America Market Attractiveness by Drug Type, 2023 to 2033

Figure 74: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 76: Europe Market Value (US$ Million) by Workflow, 2023 to 2033

Figure 77: Europe Market Value (US$ Million) by Therapeutics Area, 2023 to 2033

Figure 78: Europe Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 79: Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 84: Europe Market Value (US$ Million) Analysis by Workflow, 2018 to 2033

Figure 85: Europe Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033

Figure 86: Europe Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033

Figure 87: Europe Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033

Figure 88: Europe Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033

Figure 89: Europe Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033

Figure 90: Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 91: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 92: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 93: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 94: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 95: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 96: Europe Market Attractiveness by Workflow, 2023 to 2033

Figure 97: Europe Market Attractiveness by Therapeutics Area, 2023 to 2033

Figure 98: Europe Market Attractiveness by Drug Type, 2023 to 2033

Figure 99: Europe Market Attractiveness by End User, 2023 to 2033

Figure 100: Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: South Asia Market Value (US$ Million) by Workflow, 2023 to 2033

Figure 102: South Asia Market Value (US$ Million) by Therapeutics Area, 2023 to 2033

Figure 103: South Asia Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 104: South Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 105: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 106: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 109: South Asia Market Value (US$ Million) Analysis by Workflow, 2018 to 2033

Figure 110: South Asia Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033

Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033

Figure 112: South Asia Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033

Figure 113: South Asia Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033

Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033

Figure 115: South Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 116: South Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 118: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 119: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 120: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 121: South Asia Market Attractiveness by Workflow, 2023 to 2033

Figure 122: South Asia Market Attractiveness by Therapeutics Area, 2023 to 2033

Figure 123: South Asia Market Attractiveness by Drug Type, 2023 to 2033

Figure 124: South Asia Market Attractiveness by End User, 2023 to 2033

Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 126: East Asia Market Value (US$ Million) by Workflow, 2023 to 2033

Figure 127: East Asia Market Value (US$ Million) by Therapeutics Area, 2023 to 2033

Figure 128: East Asia Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 129: East Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 130: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 131: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 134: East Asia Market Value (US$ Million) Analysis by Workflow, 2018 to 2033

Figure 135: East Asia Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033

Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033

Figure 137: East Asia Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033

Figure 138: East Asia Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033

Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033

Figure 140: East Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 141: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 143: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 144: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 145: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 146: East Asia Market Attractiveness by Workflow, 2023 to 2033

Figure 147: East Asia Market Attractiveness by Therapeutics Area, 2023 to 2033

Figure 148: East Asia Market Attractiveness by Drug Type, 2023 to 2033

Figure 149: East Asia Market Attractiveness by End User, 2023 to 2033

Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 151: Oceania Market Value (US$ Million) by Workflow, 2023 to 2033

Figure 152: Oceania Market Value (US$ Million) by Therapeutics Area, 2023 to 2033

Figure 153: Oceania Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 154: Oceania Market Value (US$ Million) by End User, 2023 to 2033

Figure 155: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 156: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 159: Oceania Market Value (US$ Million) Analysis by Workflow, 2018 to 2033

Figure 160: Oceania Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033

Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033

Figure 162: Oceania Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033

Figure 163: Oceania Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033

Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033

Figure 165: Oceania Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 166: Oceania Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 168: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 169: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 170: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 171: Oceania Market Attractiveness by Workflow, 2023 to 2033

Figure 172: Oceania Market Attractiveness by Therapeutics Area, 2023 to 2033

Figure 173: Oceania Market Attractiveness by Drug Type, 2023 to 2033

Figure 174: Oceania Market Attractiveness by End User, 2023 to 2033

Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 176: MEA Market Value (US$ Million) by Workflow, 2023 to 2033

Figure 177: MEA Market Value (US$ Million) by Therapeutics Area, 2023 to 2033

Figure 178: MEA Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 179: MEA Market Value (US$ Million) by End User, 2023 to 2033

Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 184: MEA Market Value (US$ Million) Analysis by Workflow, 2018 to 2033

Figure 185: MEA Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033

Figure 186: MEA Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033

Figure 187: MEA Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033

Figure 188: MEA Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033

Figure 189: MEA Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033

Figure 190: MEA Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 191: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 192: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 193: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 194: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 195: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 196: MEA Market Attractiveness by Workflow, 2023 to 2033

Figure 197: MEA Market Attractiveness by Therapeutics Area, 2023 to 2033

Figure 198: MEA Market Attractiveness by Drug Type, 2023 to 2033

Figure 199: MEA Market Attractiveness by End User, 2023 to 2033

Figure 200: MEA Market Attractiveness by Country, 2023 to 2033